Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
60S ribosomal protein L36 (RPL36)
- Target
- RPL36
- Molecular classification
- Ribosomal protein
01
Overview
60S ribosomal protein L36 (RPL36) is a highly conserved structural component of the large (60S) ribosomal subunit, encoded by the human RPL36 gene. It belongs to the L36E family, is located in the cytoplasm, and is essential for ribosome assembly and catalytic protein synthesis. RPL36 also exhibits diverse biological functions beyond structural roles; it promotes cell proliferation and cell cycle progression (notably in glioma), and its alternative protein product (alt-RPL36) modulates cell size and PI3K-AKT-mTOR signaling via interaction with TMEM24. Aberrant expression of RPL36 is observed in hepatocellular carcinoma, where it serves as an independent prognostic marker. Epigenetic mechanisms adjusting RPL36 mRNA stability are involved in cellular responses to toxic insult, such as benzene exposure. Diseases linked to RPL36 include Diamond-Blackfan anemia and pure red-cell aplasia, although direct therapeutic targeting remains unestablished.
- Other names
- ribosomal protein L36large ribosomal subunit protein eL36eL36L36DKFZp566B023
02
Biological functions
Structural constituent of ribosomeProtein synthesis (translation)Cell proliferationCell cycle regulation (facilitates G1/S transition)Regulation of PI3K-AKT-mTOR signaling
03
Disease associations
Cancer (glioma, hepatocellular carcinoma, tumorigenesis)Hematological toxicity (benzene-induced impairment)Diamond-Blackfan anemiaPure red-cell aplasia
04
Safety considerations
No specific safety concerns or therapeutic challenges cited regarding RPL36; as a ribosomal protein, inhibition could be cytotoxic and broadly impact translation.
05
Biomarkers
Prognostic marker for early-stage hepatocellular carcinoma—higher RPL36 expression associates with better survival after tumor resectionPossible biomarker for benzene hematotoxicity in the context of mRNA stability modulation
Beyond the preview
Go deeper on 60S ribosomal protein L36 (RPL36).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 60S ribosomal protein L36 (RPL36).